InvestSMART

Raptor Metals Ltd (ASX: RAP) - Announcements

- Current share price for RAP : $0.025

ASX company news and announcements for Raptor Metals Ltd (RAP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Raptor Metals Ltd (RAP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Raptor Metals Ltd (RAP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Raptor Metals Ltd (RAP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$10 Clinical Study of COPD Screening in Indigenous Australians 19 Dec 2019 9:15AM $0.255 $0.025 fallen by 90.20%
$10 ResApp Receives $1.8 Million R&D Tax Incentive Cash Rebate 12 Dec 2019 9:37AM $0.245 $0.025 fallen by 89.80%
$10 Results of Annual General Meeting 28 Nov 2019 12:07PM $0.280 $0.025 fallen by 91.07%
$10 Annual General Meeting Presentation 28 Nov 2019 9:37AM $0.270 $0.025 fallen by 90.74%
$10 ResAppDx-EU to be deployed on the Coviu Telehealth Platform 28 Nov 2019 9:09AM $0.270 $0.025 fallen by 90.74%
$10 2019 Letter to Shareholders 25 Nov 2019 9:34AM $0.290 $0.025 fallen by 91.38%
$10 ResApp Grants Option to Consumer Health Division of Sanofi 15 Nov 2019 9:18AM $0.270 $0.025 fallen by 90.74%
$10 Quarterly Update and Appendix 4C 30 Oct 2019 9:26AM $0.315 $0.025 fallen by 92.06%
$10 Notice of Annual General Meeting 28 Oct 2019 2:01PM $0.350 $0.025 fallen by 92.86%
$10 Change of Registered Office 24 Oct 2019 7:49PM $0.335 $0.025 fallen by 92.54%
$10 ResApp Joins Startup Creasphere Digital Health Program 4 Oct 2019 8:39AM $0.270 $0.025 fallen by 90.74%
$10 Change of Principal Place of Business 3 Oct 2019 4:48PM $0.270 $0.025 fallen by 90.74%
$10 TGA Approval for Paediatric Respiratory Disease Diagnosis 2 Oct 2019 9:42AM $0.247 $0.025 fallen by 89.88%
$10 Trading Halt 1 Oct 2019 1:48PM $0.248 $0.025 fallen by 89.90%
$10 Pause In trading 1 Oct 2019 1:21PM $0.248 $0.025 fallen by 89.90%
$10 Positive Results from At-Home Sleep Apnoea Study 30 Sep 2019 8:58AM $0.220 $0.025 fallen by 88.64%
$10 ResAppDx-EU for Adult Respiratory Disease Receives CE Mark 26 Sep 2019 8:41AM $0.220 $0.025 fallen by 88.64%
$10 Investor Presentation September 2019 16 Sep 2019 8:42AM $0.195 $0.025 fallen by 87.18%
$10 Appendix 4G 28 Aug 2019 1:22PM $0.210 $0.025 fallen by 88.10%
$10 Corporate Governance Statement 28 Aug 2019 1:17PM $0.210 $0.025 fallen by 88.10%
$10 Appendix 4E and Annual Report 28 Aug 2019 1:09PM $0.210 $0.025 fallen by 88.10%
$10 ResApp Receives CE Mark for ResAppDx-EU 23 Aug 2019 9:30AM $0.150 $0.025 fallen by 83.33%
$10 Trading Halt 22 Aug 2019 9:20AM $0.150 $0.025 fallen by 83.33%
$10 Quarterly Update and Appendix 4C 29 Jul 2019 9:51AM $0.160 $0.025 fallen by 84.38%
$10 Appendix 3B and Section 708A Notice 4 Jul 2019 5:04PM $0.180 $0.025 fallen by 86.11%

276 - 300 of 572 results

Page 12 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.